Becker’s ASC Review spoke with William Chey, MD, of Ritter Pharmaceuticals’ medical advisory board, about the first treatment for lactose intolerance, the company’s RP-G28. The treatment has not yet ...
LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate ...
LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate ...
LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut ...
* Has incorporated guidance from FDA on key elements of its phase 3 program to support a new drug application (NDA) for RP-G28 ...
Ritter Pharmaceuticals Inc. is reeling from the phase III failure of its lead candidate, RP-G28, designed for patients with lactose intolerance. RP-G28 failed to demonstrate statistical significance ...
* RITTER PHARMACEUTICALS INC - DURING PHASE 2A STUDY, OBSERVED AN INCREASE IN BIFIDOBACTERIA, WHICH WERE CONFIRMED IN LARGER PHASE 2B STUDY * RITTER PHARMACEUTICALS INC - PHASE 3 CLINICAL TRIAL OF ...
In September 2019, the Company announced that its Phase 3 clinical trial of RP-G28 for lactose intolerance (LI), known as “Liberatus,” failed to demonstrate statistical significance in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results